GLS and neoplasm: In contrast, Telaglenastat (CB-839) represents a potent, orally bioavailable GLS inhibitor showing anti-tumour activity in transplantable cancer models, including breast cancer and lymphoma30,31, and ongoing clinical trials are examining efficacy in haematologic and solid cancers32.